Knock-in Mouse Model for Alzheimer's Disease Pathology Reproduction

Solution Overview

Problem

Current Alzheimer's disease models, such as the Tg2576 mouse, fail to adequately reproduce the series of pathologies observed in human Alzheimer's brains, including Aβ accumulation, neurofibrillary tangle formation, and neurodegeneration, due to non-physiological APP overexpression and random transgene insertion, which can lead to incomplete pathology replication.

Innovation Solution

A knock-in mouse model is developed by substituting the Aβ portion of the mouse APP gene with the human sequence and introducing specific mutations to increase Aβ42 production, achieving a significantly higher Aβ42/Aβ40 ratio without overexpressing APP, thus replicating the full spectrum of AD pathologies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If APP is overexpressed in transgenic mice to increase Aβ production, then Aβ accumulation is improved, but non-physiological expression influences axonal transport and produces neuroprotective fragments that suppress neurodegeneration

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The invention applies local quality by specifically modifying only the Aβ coding region (exons 16-18) of the endogenous APP gene while preserving the rest of the APP gene structure and its native promoter. This localized substitution ensures that only the Aβ peptide sequence is altered to match human sequence with FAD mutations, while the physiological regulation of APP expression remains intact, avoiding the artifacts of global APP overexpression.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The invention uses copying by substituting the mouse Aβ coding sequence with the human Aβ coding sequence containing FAD mutations. This creates a knock-in model where the human-like Aβ is produced under the control of the mouse APP gene's native regulatory elements, accurately replicating the human disease mechanism without the need for foreign transgene expression systems.

Inventive Principle:
Principle #26Copying

2Quantity of substance

If transgenes are randomly inserted into chromosomes to create AD models, then Aβ production is increased, but gene expression levels vary between generations and insertion site effects occur

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The invention applies preliminary action by using homologous recombination to precisely target the APP gene locus before the actual Aβ sequence substitution. The targeting vector is designed with homology arms that match the endogenous APP gene, ensuring site-specific integration. This preliminary targeting step prevents random insertion and ensures that the Aβ-modified APP gene is always inserted at the correct physiological location with consistent expression across generations.

Inventive Principle:
Principle #10Preliminary action

3Quantity of substance

If promoters of prion protein, PDGF, or Thy-1 are used to drive APP expression, then Aβ is produced from neuronal cells other than those intrinsically expressing APP, but this creates non-physiological Aβ production patterns

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSEase of operation

Solution Approach 1:

The invention applies the taking out principle by removing the foreign promoter elements (prion protein, PDGF, or Thy-1 promoters) that were previously used to drive APP expression. Instead, the invention retains only the native APP gene promoter and regulatory elements, extracting away the non-physiological components while preserving the endogenous expression pattern. This ensures Aβ is produced only in the specific neuronal cells that naturally express APP.

Inventive Principle:
Principle #2Taking out (Extraction)

Data Source

PatentEP1870472B1Model animal of Alzheimer's disease and use thereof
Publication Date: 2011.11.23
  • EP1870472B1 patent drawingFigure 1
  • EP1870472B1 patent drawingFigure 2
  • EP1870472B1 patent drawingFigure 3a~3b

AI summary

The present invention provides a non-human model mammal of Alzheimer's disease (AD) containing chimeric amyloid precursor protein (APP) gene capable of producing human amyloid β peptide (Aβ) or a living part thereof, characterized in that Aβ42/Aβ40 ratio at 8-weeks-old is about 7-fold or more (about 140-fold or more in homozygote) higher compared to that of a corresponding wild-type mammal. Moreover, the present invention provides the mammal or a living part thereof, further characterized in that the level of APP expression is not significantly different compared to the corresponding wild-type mammal, and a screening method for a prophylactic and/or therapeutic drug for AD, a biomarker in biological fluids and molecular imaging of amyloid deposition or other pathological changes in the brain for an early diagnosis of AD using the mammal or a living part thereof.